Michael Choy
Managing Director & Partner
New Jersey
Michael Choy joined Boston Consulting Group in 2005 and previously worked in the San Francisco and Shanghai offices. He is currently leading BCG's work in the U.S. on scenario analysis of COVID-19 health impacts. He also leads the firm’s work in cell and gene therapy, defining strategies and operations for new therapeutic modalities.
Michael has extensive experience serving industry-leading clients in the U.S., Europe, and Asia on high-impact programs, developing strategies, delivering innovative solutions, leading large teams, guiding executive decision-making, and driving client relationships. He has worked with clients on R&D, manufacturing, and commercialization of new medicines; large-scale change and PMI; R&D governance, organization, and operations; population health and disease surveillance; market access and commercialization; and global health.
Michael is an epidemiologist by training, and has held research positions at Stanford and the University of California, San Francisco.
Companies can maximize the value of large-scale mergers by proactively implementing a transparent, disciplined talent-selection process.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
These curative treatments are often unique. They face a very different type of marketplace.
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.
